AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development
Strategic partnership reflects AC Immune’s growing expertise in monoclonal antibody development
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases and WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, today unveiled plans to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications.